Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.36 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.35 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10022231 | 0.94 | P2RY2 (0.40) | POLGP2RY2P2RY4P2RY6 | |
| SCHEMBL10020460 | 0.94 | P2RY2 (0.40) | POLGP2RY2P2RY4P2RY6 | |
| SCHEMBL13654806 | 0.83 | CA2 (0.41) | P2RY2P2RY11P2RX3P2RX4P2RX2 | |
| SCHEMBL22415081 | 0.83 | CA2 (0.41) | P2RY2P2RY11P2RX3P2RX4P2RX2 | |
| SCHEMBL10022250 | 0.83 | CA2 (0.41) | P2RY2P2RY11P2RX3P2RX4P2RX2 | |
| SCHEMBL17833854 | 0.82 | POLG (0.43) | POLGP2RY2P2RY4P2RY6 | |
| SCHEMBL12729532 | 0.82 | POLG (0.43) | POLGP2RY2P2RY4P2RY6 | |
| SCHEMBL10053469 | 0.81 | P2RX3 (0.40) | P2RY2P2RY11P2RX3P2RX4P2RX2 | |
| SCHEMBL13901157 | 0.80 | DNMT1 (0.34) | — | |
| SCHEMBL13224522 | 0.80 | P2RY2 (0.39) | POLGP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114973-B2 | Nucleotide analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090186351-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186351-A1 | NUCLEOTIDE ANALOGS | NT5C3B, RNGTT, NT5C2 | POLG 166/4885P2RY2 289/4885P2RY4 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.